Psychedelic Science Revival

The Psychedelic Science Revival marks the return of psychedelic research to public institutions after a long interruption, but it is more than a scientific comeback. It reconnects clinical work with practices and knowledge that survived underground, while forcing medicine to confront an unusual problem: the drug, the therapeutic relationship, the participant’s expectations, and the setting may all contribute to the experience being studied. Its growing legitimacy has therefore depended on both renewed evidence and careful negotiation over what counts as science, therapy, and responsible use.

From the First Wave to a Renewed Inquiry

The revival picked up a research thread dropped in the 1970s, when sanctioned psychedelic therapy ended. The earlier work had already explored many of the questions under consideration again, but the intervening break meant that findings and practices had to be recovered and tested anew. Charles Grob, whose 2011 pilot study of psilocybin for cancer anxiety helped clear a path for later trials at New York University and Johns Hopkins, described the new work as taking up a torch earlier researchers had been forced to put down under cultural pressure. To gain acceptance in modern medicine, this inherited knowledge would need to be examined again under prevailing scientific standards.

The renewed research did not begin from a blank slate. During the years when psychedelic treatment was still legal, practitioners and researchers had developed approaches that continued to circulate through personal and professional lineages. The underground guides interviewed by the book often traced their training back to Timothy Leary, Stanislav Grof, Al M. Hubbard, or Leo Zeff, sometimes through a graduate student. Zeff, who died in 1988, said that he had worked with three thousand patients and trained 150 guides. Myron Stolaroff later argued that research resuming in the late 1990s had developed partly from such underground therapists’ anecdotal evidence, as well as from the first wave of formal studies.

That continuity was not simply theoretical. Some underground therapists helped train guides for university trials, and when the Johns Hopkins team investigated music in guided psilocybin sessions, it consulted underground practitioners about their musical practices. The exchange exposed an informal history of knowledge transfer that institutional accounts might otherwise leave out: practices developed beyond the bounds of sanctioned research could still shape how later clinical work was conducted.

Networks Beneath and Between Institutions

The revival’s ancestry includes an earlier network built through travel, training, shared supplies, and personal contact. By the late 1950s, Al M. Hubbard moved among research centers in Canada and the United States, working with Humphry Osmond and Abram Hoffer in Weyburn, meeting R. Gordon Wasson in Manhattan, and sharing techniques and LSD with researchers including Betty Eisner, Sidney Cohen, and Oscar Janiger in Los Angeles. He also helped establish LSD treatment for alcoholism at Canadian facilities. In Menlo Park, Myron Stolaroff and colleagues from Ampex met to consider LSD’s potential for healthy people, and Hubbard guided their sessions and trained participants to guide others. This history illustrates how psychedelic knowledge had already traveled through networks that crossed the boundaries between medicine, research, and broader ideas of human potential.

The revived field’s connections were still difficult to see from the outside. In 2010, James Fadiman attended a Bay Area conference on psychedelic science and invited underground guides in the audience to meet the following morning. He expected only a handful; a hundred people appeared. The gathering did not turn the dispersed practitioners into a formal organization, but it made their scale and shared practices more visible. Fadiman had come to speak about guided entheogenic journeys, and the unexpectedly large turnout revealed a community that existed alongside academic trials, with points of contact between the two.

The 2017 Psychedelic Science conference offered a strikingly larger public measure of change. Organized by the Multidisciplinary Association for Psychedelic Studies, it brought more than three thousand people to the Oakland Convention Center over six days. Researchers from twenty-five countries presented findings alongside therapists, underground guides, shamans, experienced users, funders, filmmakers, and entrepreneurs. A conference that had been a modest gathering of researchers and psychonauts in 2010 had become a crowded meeting place for institutions and practices that once occupied sharply separated worlds.

The Scientific and Spiritual Boundary

The renewed clinical program challenged psychiatry in a way earlier models had not. Psychotomimetic accounts treated drug effects as resembling mental illness, while psycholytic treatment could be fitted into psychoanalytic practice as an aid to talking therapy. The psychedelic model instead proposed a single high-dose session aimed at a conversion-like experience, requiring a rethinking of the roles of both patient and therapist. Its spiritual dimension and reliance on set and setting unsettled a profession increasingly committed to biochemical accounts of the mind. Charles Grob described this approach as applied mysticism, a phrase that made the boundary between medical science and religious experience unusually difficult to keep firm.

The research methods themselves sharpened the problem. Participants and guides can often tell whether psilocybin or a placebo has been administered, making conventional blinding difficult. Researchers also have trouble isolating the chemical’s effects from the setting, the therapists’ presence, and participants’ expectations. These factors complicate causal claims under a model of drug testing built around separating one variable from another. The question is not only whether a psychedelic changes symptoms, but how medicine can evaluate a treatment in which the experience itself may be part of the therapeutic action.

At the 2017 conference, the tension between innovation and institutional caution was voiced by figures from the mental-health establishment. A panel on the future of psychedelic psychiatry included Paul Summergrad, former head of the American Psychiatric Association, and Tom Insel, former head of the National Institute of Mental Health. Insel praised the emphasis on psychedelic-assisted psychotherapy rather than simply administering a drug, while warning that the model could be difficult for regulators accustomed to evaluating medicines in isolation. He and Summergrad also stressed safety, research rigor, and reputational risk: one careless investigator or disastrous patient experience, they warned, could damage the prospects of the field as a whole.

Recognition, Legacy, and Unfinished Work

Institutional progress became tangible in the expanding clinical agenda. The New York University and Johns Hopkins studies examined psychedelics as possible support for people confronting death, while other trials investigated depression and addictions including alcohol, cocaine, and tobacco. The growing interest in psilocybin and the renewed testing of MDMA suggested that the field was no longer confined to historical debate or underground practice. The Multidisciplinary Association for Psychedelic Studies, founded by Rick Doblin in 1986 to support research and public understanding, became a major force in that transition. The FDA approved phase-three MDMA trials in 2016 and designated MDMA a breakthrough therapy in 2017; psilocybin research was also approaching a new stage of clinical testing.

The revival also complicates the story of the first wave’s collapse. Doblin argued that Timothy Leary’s influence helped make a later generation familiar with psychedelics, including people who would eventually hold positions within major institutions. Paul Summergrad, for example, had spoken publicly about the formative intellectual effect of youthful psychedelic use. The cultural reach associated with Leary could be blamed for damaging research, but it also helped create a public and professional constituency through which research might return.

By the close of the book, the revival is presented as both a remarkable opening and a precarious negotiation. The Oakland conference embodied a new proximity between guides, researchers, clinicians, and institutional leaders, but proximity was not the same as settled acceptance. The work still had to demonstrate safety and rigor, withstand regulatory scrutiny, and find ways to study experiences whose meaning may depend on more than pharmacology alone. Its defining achievement was to reopen the inquiry; its unresolved task was to make room for that complexity without losing scientific credibility.